We traveled to Kansas City, Missouri, for a State of the Science Summit™ on Advanced Non–Small Cell Lung Cancer, which focused on recent progress made in squamous NSCLC and small cell lung cancer, provided tips on how to navigate the complex paradigm of oncogene-driven disease, and shed light on emerging biomarkers in the space.

We traveled to Memphis, Tennessee for a State of the Science Summit™ on Genitourinary Cancers, which focused on advances made in the treatment landscapes of metastatic renal cell carcinoma and prostate cancer.

We traveled to New York, New York, for a State of the Science Summit™ on Advanced Non–Small Cell Lung Cancer, which focused on topics ranging from surgical techniques, to headway made in immunotherapy, to emerging biomarkers, to diagnostic advancements.

We traveled to Minneapolis, Minnesota, for a State of the Science Summit on Breast Cancer, which focused on surgical approaches for node-positive breast cancer, the use of CDK4/6 inhibitors in hormone receptor–positive disease, and emerging drug therapies in triple-negative disease.

We traveled to Syracuse, New York, for a State of the Science Summit on Advanced Non–Small Cell Lung Cancer, which focused on practice-change clinical trials in the space, as well as novel approaches to treatment with checkpoint inhibitors, targeted therapies, radiation, and minimally invasive surgery.

We traveled to New York City, New York, for a State of the Science Summit on Multiple Myeloma, which focused on stem cell transplant, minimal residual disease, maintenance options, and treatment approaches for newly diagnosed myeloma.

We traveled to Washington D.C. for a State of the Science Summit on Breast Cancer, which focused on additional recent advances in the NSCLC and small cell lung cancer paradigms, touching on TKIs, immunotherapy, and other investigational agents.

We traveled to Pittsburgh, Pennsylvania for a State of the Science Summit on Breast Cancer, which focused on novel approaches in metastatic triple-negative breast cancer and treatment strategies for patients with brain metastases.

We headed to Stanford, California, for a State of the Science Summit on Ovarian Cancer and Soft Tissue Sarcoma, which focused on recent advances made in the treatment landscapes.

We headed to Chicago, Illinois, for a State of the Science Summit on Advanced Non–Small Cell Lung Cancer, which focused on recent updates in the field, particularly data from the 2018 World Conference on Lung Cancer.

We headed to Charlotte, North Carolina, for a State of the Science Summit on Genitourinary Cancers, which focused on the evolving paradigms of prostate cancer and renal cell carcinoma.

We headed to Clayton, Missouri for a State of the Science Summit on Hematologic Malignancies, which focused on novel agents in chronic lymphocytic leukemia, advances in acute myeloid leukemia, progress in myeloproliferative neoplasms, and more.

We headed to Newport Beach, California, for a State of the Science Summit on Gastrointestinal Cancers, which focused on the evolving paradigms of colorectal cancer, pancreatic cancer, neuroendocrine tumors, gastric cancer, and hepatocellular carcinoma.

We visited Summit, New Jersey for a State of the Science Summit on non–small cell lung cancer (NSCLC). The meeting covered the current standard of care for early-stage lung cancer, approaches to locoregionally advanced NSCLC, updates in EGFR-positive NSCLC, and more.

We traveled to Cleveland, Ohio for a State of the Science Summit on Hematologic Malignancies. The meeting covered the evolving paradigm of chronic lymphocytic leukemia, updates in mantle cell lymphoma, treatment options for patients with newly diagnosed and relapsed/refractory multiple myeloma, unmet needs in myeloproliferative neoplasms, interesting genomic research in acute myeloid leukemia, and the challenges with treating patients with myelodysplastic syndrome.

We returned to San Francisco, California for a State of the Science Summit on Breast Cancer. The meeting covered the use of CDK4/6 inhibitors in metastatic hormone receptor-positive breast cancer, adjuvant and neoadjuvant HER2-targeted therapy in early-stage HER2-positive disease, immunotherapy in triple-negative disease, and more.

We visited San Francisco, California for a State of the Science Summit on Hematologic Malignancies. The meeting covered novel agents and combinations in lymphoma, updates in acute and chronic leukemias, and modalities in the management of multiple myeloma.

We visited Chicago, Illinois for a State of the Science Summit on Renal Cell Carcinoma and Bladder Cancer. The meeting covered the genomics of bladder cancer, novel approaches to non-muscle invasive bladder cancer, side effect management from immunotherapy, as well as the integration of immunotherapy, chemotherapy, and targeted therapy in genitourinary cancers.

We traveled to Seattle, Washington for another State of the Science Summit on Hematologic Malignancies with faculty of Seattle Cancer Care Alliance and Fred Hutchinson Cancer Research Center. The meeting covered the latest updates in Hodgkin lymphoma, mantle cell lymphoma, multiple myeloma, and more.

We visited Dearborn, Michigan for a State of the Science Summit on Hematologic Malignancies with faculty of Karmanos Cancer Institute.

We headed to Tampa, Florida for a State of the Science Summit on Hematologic Malignancies. The meeting covered updates in follicular lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, multiple myeloma, acute lymphoblastic leukemia, chronic myeloid leukemia, acute myeloid leukemia, myeloproliferative neoplasms, and CAR T-cell therapy.

We traveled to Hanover, Maryland for a State of the Science SummitTM on Advanced Non–Small Cell Lung Cancer. The meeting covered the use of immunotherapy in metastatic and early-stage disease, management of immune-related toxicities, predictive biomarkers, and emerging therapies in small cell lung cancer.

We traveled to Charlotte, North Carolina for a State of the Science Summit on Ovarian Cancer. The meeting covered genetic testing, frontline therapies, surgical options, treatment for recurrent disease, immunotherapy, and updates in uterine sarcomas.

This Dallas, Texas meeting on gastrointestinal (GI) cancers covered emerging therapies in pancreatic cancer, updates in neuroendocrine tumors, the management of metastatic colorectal cancer, recent data in hepatocellular carcinoma, and the clinical application of precision medicine in GI cancers.

We traveled to Charlottesville, Virginia for a State of the Science Summit on Advanced Non-Small Cell Lung Cancer. The conference spanned early-stage advances, established and emerging treatments for oncogenic-driven disease, chemotherapy, immunotherapy, and the role of radiation

We went out to Denver, Colorado for a State of the Science Summit on Advanced Non–Small Cell Lung Cancer. The conference spanned screening, molecular profiling, early-stage advances, treatment for oncogenic-driven advanced disease, and immunotherapy.

We traveled to Houston, Texas for a State of the Science Summit on Breast Cancer on July 11, 2018. The conference covered radiation therapy, triple-negative breast cancer, BRCA-positive tumors, takeaways from the 2018 ASCO Annual Meeting, and more.

We headed out to Kansas City, Missouri, for a State of the Science Summit on June 30, 2018, which spanned several tumor types and covered the highlights from the 2018 ASCO Annual Meeting.